Drugs

, Volume 71, Issue 15, pp 2067–2077

Abiraterone Acetate

In Metastatic Castration-Resistant Prostate Cancer
Adis Drug Profile

Abstract

Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone.

In a pivotal phase III trial in patients with metastatic CRPC who have previously received docetaxel-containing chemotherapy, abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily significantly prolonged overall survival compared with placebo plus prednisone.

In this trial, abiraterone acetate plus prednisone was significantly more effective than placebo plus prednisone in prolonging the time to prostate-specific antigen (PSA) progression and in prolonging progression-free survival. Significantly more abiraterone acetate plus prednisone recipients than placebo plus prednisone recipients were considered to be responders, when assessed by PSA levels or radiographic imaging.

Treatment with abiraterone acetate plus prednisone in the phase III trial was associated with an acceptable tolerability profile, which was generally similar to that of the placebo plus prednisone group. However, adverse events of special interest (e.g. cardiac disorders and liver-function test abnormalities and adverse events resulting from elevated mineralocorticoid levels because of CYP17A1 inhibition [i.e. fluid retention and oedema, hypokalaemia, hypertension]) occurred in significantly more abiraterone acetate plus prednisone than in placebo plus prednisone recipients.

References

  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010 Mar; 46(4): 765–81PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [published errata appears in CA Cancer J Clin 2011 Mar–Apr; 61 (2): 133, 134]. CA Cancer J Clin 2010 Sep–Oct; 60(5): 277–300PubMedCrossRefGoogle Scholar
  3. 3.
    Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (overview), 1975–2008, National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/csr/1975_2008/results_merged/sect_01_overview.pdf [Accessed 2011 Sep 16]
  4. 4.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): prostate cancer (version 4.2011) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf [Accessed 2011 Sep 16]
  5. 5.
    Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011 Jan; 59(1): 61–71Google Scholar
  6. 6.
    Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: v129–33PubMedCrossRefGoogle Scholar
  7. 7.
    Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011 Apr; 59(4): 572–83Google Scholar
  8. 8.
    Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004 Jan; 10(1): 33–9PubMedCrossRefGoogle Scholar
  9. 9.
    Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007 Apr; 4(4): 236–44PubMedCrossRefGoogle Scholar
  10. 10.
    Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011 Sep 15; 17(18): 5844–9PubMedCrossRefGoogle Scholar
  11. 11.
    Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011 Apr 23; 4(1): 18PubMedCrossRefGoogle Scholar
  12. 12.
    Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 2010 Sep 1; 16(17): 4319–24PubMedCrossRefGoogle Scholar
  13. 13.
    Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 Mar 1; 26(7): 1148–59PubMedCrossRefGoogle Scholar
  14. 14.
    Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 2011 Mar; 34(3): 232–43PubMedGoogle Scholar
  15. 15.
    Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008 Jan 10; 26(2): 242–5PubMedCrossRefGoogle Scholar
  16. 16.
    Janssen-Cilag Ltd. Zytiga (abiraterone acetate) 250mg tablets: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/24976/SPC/Zytiga+250+mg+tablets/ [Accessed 2011 Sep 16]
  17. 17.
    Centocor Ortho Biotech Inc. Zytiga™ (abiraterone acetate) oral tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf [Accessed 2011 Sep 16]
  18. 18.
    Attard G, Reid AHM, Olmos D, et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009 Jun 15; 69(12): 4937–40PubMedCrossRefGoogle Scholar
  19. 19.
    Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 Apr 1; 17(7): 1649–57PubMedCrossRefGoogle Scholar
  20. 20.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004 Mar 15; 22(6): 1025–33PubMedCrossRefGoogle Scholar
  21. 21.
    Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism of castration-resistant tumor growth. Cancer Res 2008 Jun 1; 68(11): 4447–54PubMedCrossRefGoogle Scholar
  22. 22.
    Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009 Mar 10; 100(5): 671–5PubMedCrossRefGoogle Scholar
  23. 23.
    Attard G, Reid AHM, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008 Oct 1; 26(28): 4563–71PubMedCrossRefGoogle Scholar
  24. 24.
    Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P450 17α (17α-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995 Jun 23; 38(13): 2463–71PubMedCrossRefGoogle Scholar
  25. 25.
    Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010 Mar 20; 28(9): 1481–8PubMedCrossRefGoogle Scholar
  26. 26.
    Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010 Mar 20; 28(9): 1496–501PubMedCrossRefGoogle Scholar
  27. 27.
    Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010 Mar 20; 28(9): 1489–95PubMedCrossRefGoogle Scholar
  28. 28.
    Attard G, Reid AHM, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009 Aug 10; 27(23): 3742–8PubMedCrossRefGoogle Scholar
  29. 29.
    de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 May 26; 364(21): 1995–2005PubMedCrossRefGoogle Scholar
  30. 30.
    Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011 Aug 30; 18(5): R175–182PubMedCrossRefGoogle Scholar
  31. 31.
    Mostaghel EA, Marck BT, Plymate S, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011 Sep 15; 17(18): 5913–25PubMedCrossRefGoogle Scholar
  32. 32.
    Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. Epub 2011 Aug 25Google Scholar
  33. 33.
    Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract no. LBA4517]. J Clin Oncol 2011 Jun 20; 29 (18 Suppl.)Google Scholar
  34. 34.
    Fizazi K, Scher HI, Molina A, et al. Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel [abstract no. 7000]. 2011 European Multidisciplinary Cancer Congress; 2011 Sep 23–27; StockholmGoogle Scholar
  35. 35.
    Harland S, de Bono JS, Haqq CM, et al. Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: results from the COU-AA-301 phase 3 study [abstract no. 7001]. 2011 European Multidisciplinary Cancer Congress; 2011 Sep 23–27; StockholmGoogle Scholar
  36. 36.
    Sternberg CN, Scher HI, Molina A, et al. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: results from the COU-AA-301 phase 3 study [abstract no. 7015]. 2011 European Multidisciplinary Cancer Congress; 2011 Sep 23–27; StockholmGoogle Scholar
  37. 37.
    Bianchini D. Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC) [abstract no. 4672]. J Clin Oncol 2010 May 20; 28 (15 Suppl.)Google Scholar
  38. 38.
    Cougar Biotechnology Inc. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer [ClinicalTrials.gov identifier NCT00887198]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Sep 16]

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations